This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Merck CEO Talks Growth

Updated from 7:55 a.m. EST

Merck (MRK) released fourth-quarter earnings that beat Wall Street's estimates, as sales held steady while restructuring and legal costs were slightly lower in the latest period.

The drugmaker also issued 2006 guidance that was in line with analysts' predictions. Merck's sliding financial performance could hit its nadir this year, thanks to the continuing impact of patent expirations on big products, as well as the continuing uncertainty over Vioxx litigation.

Beyond this year, Merck's progress will depend on how well new drugs perform, how many experimental compounds make it to the market, how effectively Merck makes licensing deals or acquisitions and how juries react to Vioxx.

Merck took a $295 million charge in the fourth quarter, adding to the litigation reserve for the arthritis drug that it withdrew from the market in September 2004 for safety reasons.

Already, Merck has spent $285 million to defend Vioxx cases. The reserve now stands at $685 million. As of Dec. 31, Merck was the defendant in 9,650 U.S. personal injury suits and 190 class-action suits alleging personal injuries or economic losses.

Despite its Vioxx woes, Merck reported fourth-quarter earnings of 64 cents a share, excluding one-time items. That topped by 2 cents the consensus estimate of analysts polled by Thomson First Call.

Calculated by generally accepted accounting principles, Merck earned $1.12 billion, or 51 cents a share, compared with $1.10 billion, or 50 cents a share, for the same period last year. Sales were $5.77 billion in the latest quarter, compared with $5.75 billion a year ago.

For the full year, Merck's earnings per share of $2.53, before items, was 2 cents better than the analyst average.

By midday, Merck's stock was up 12 cents to $34.58.

Richard T. Clark, the CEO, said the fourth-quarter and full-year performance "serves as a platform for the future." He says the company can deliver "double-digit compound earnings growth ... over the next three to five years" when restructuring charges are excluded. Earnings per share, excluding restructuring charges, should resume growing in 2007, he says.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs